Brand Index Methodology
The Morning Consult Brand Index is an indicator of brand strength among consumers. Each Fortune 500 company receives a score based on a ratio of favorable to unfavorable impressions among U.S. adults and its overall favorability. This ensures that a score takes into account how well-liked a company is among people who have an opinion of it without penalizing companies that are not consumer-facing.
Morning Consult polls thousands of adults across the country each week. The surveys are conducted online using large, established online survey vendors. The data is weighted to approximate a nationally representative sample based on age, race/ethnicity, gender, educational attainment, region, annual household income, home ownership status and marital status.
Last year marked the end of an era for Pfizer. As the company’s patent exclusivity expired for Viagra, its blockbuster erectile dysfunction drug, the pharmaceutical giant has struggled to discover its next big hit. In January, Pfizer discontinued its research into treatments for Alzheimer’s and Parkinson’s. And after long resisting calls to split itself up, the company is now mulling whether to sell its consumer healthcare business to suitors such as Procter & Gamble. Meanwhile Pfizer, which acquired biosimilars maker Hospira in 2015, is still working to address that company’s manufacturing issues, which have led to drug shortages.
CEO
Ian C. Read
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York City
Website
Years on Fortune 500 List
24
Employees
90,200
SPONSOR CENTER
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | $52,546 | -0.5% |
| Profits ($M) | $21,308.0 | 195.3% |
| Assets ($M) | $171,797 | |
| Total Stockholder Equity ($M) | $71,308 | |
| Market Value — as of March 29, 2018 ($M) | $211,115 |
| Profit as % of Revenues | 40.6% | |
| Profits as % of Assets | 12.4% | |
| Profits as % of Stockholder Equity | 29.9% |
| Earnings Per Share ($) | 3.52 | |
| EPS % Change (from 2016) | 200.9% | |
| EPS % Change (5 year annual rate) | 12.7% | |
| EPS % Change (10 year annual rate) | 11.6% |
| Total Return to Investors (2017) | 15.7% | |
| Total Return to Investors (5 year, annualized) | 11.4% | |
| Total Return to Investors (10 year, annualized) | 9.3% |
- Previous Close:
- Market Cap: NaNB
- Next Earnings Date:
- High:
- Low:
- 52 Week High:
- 52 Week Low:
- 52 Week Change %: 0.00
- P/E Ratio: n/a
- EPS:
- Dividend Yield: n/a
News about Pfizer
The inside story of how one company—Pfizer—and one bad acquisition has led to a dangerous hospital crisis.
Must-read business news, delivered every morning.
Pfizer stock was down more than 4%, while Merck fell 2% despite beating profit expectations.
Revenue overall rose just 1% to $12.9 billion last quarter, lower than the $13.1 billion projected by analysts.
Alzheimer's drug development has been a tale of heartbreaks and setbacks.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc.. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions